Identified Medications Causing Medication-Related Osteonecrosis of the Jaw: A Literature Review

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F25%3A10499504" target="_blank" >RIV/00669806:_____/25:10499504 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/25:10499504

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=MQE8-srelM" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=MQE8-srelM</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.7759/cureus.86645" target="_blank" >10.7759/cureus.86645</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Identified Medications Causing Medication-Related Osteonecrosis of the Jaw: A Literature Review

Popis výsledku v původním jazyce

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse event that occurs in patients treated with certain medications, leading to a major side effect that can result in substantial morbidity. MRONJ is known to be associated with antiresorptive (AR) and antiangiogenic (AA) medicines, but recent evidence suggests that other medications may also be involved. Recognizing a broad range of drug-induced risk factors is important, notably in light of the increasing number of drugs associated with MRONJ. The primary objective of this review is to update and synthesize findings from the past 22 years (2003 to April 2025) regarding medications associated with MRONJ, expanding beyond the traditional AR and AA drugs to include more recent and developing therapeutic classes. This review combines findings from recent literature, including studies on AR and AA medications, as well as other drug classes, such as targeted cancer therapies and immunomodulatory agents. This review provides updated insights into MRONJ for healthcare practitioners and dentists, emphasizing the significance of risk assessment, early recognition, and multidisciplinary management to improve patient care and outcomes. Given its potential to cause significant morbidity and complicate dental and medical treatments, MRONJ presents a critical concern in clinical practice, underscoring the need for heightened awareness among healthcare professionals.

Název v anglickém jazyce

Identified Medications Causing Medication-Related Osteonecrosis of the Jaw: A Literature Review

Popis výsledku anglicky

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse event that occurs in patients treated with certain medications, leading to a major side effect that can result in substantial morbidity. MRONJ is known to be associated with antiresorptive (AR) and antiangiogenic (AA) medicines, but recent evidence suggests that other medications may also be involved. Recognizing a broad range of drug-induced risk factors is important, notably in light of the increasing number of drugs associated with MRONJ. The primary objective of this review is to update and synthesize findings from the past 22 years (2003 to April 2025) regarding medications associated with MRONJ, expanding beyond the traditional AR and AA drugs to include more recent and developing therapeutic classes. This review combines findings from recent literature, including studies on AR and AA medications, as well as other drug classes, such as targeted cancer therapies and immunomodulatory agents. This review provides updated insights into MRONJ for healthcare practitioners and dentists, emphasizing the significance of risk assessment, early recognition, and multidisciplinary management to improve patient care and outcomes. Given its potential to cause significant morbidity and complicate dental and medical treatments, MRONJ presents a critical concern in clinical practice, underscoring the need for heightened awareness among healthcare professionals.

Druh

J_ost - Ostatní články v recenzovaných periodicích

CEP obor

—

OECD FORD obor

30208 - Dentistry, oral surgery and medicine

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Curēus

ISSN

2168-8184

e-ISSN

2168-8184

Svazek periodika

17

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

17

Strana od-do

e86645

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—